Anavex Life Sciences Corp. (NASDAQ:AVXL) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus price target of $15.00 for the company and are predicting that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Anavex Life Sciences Corp. an industry rank of 115 out of 265 based on the ratings given to related companies.

A number of research firms have weighed in on AVXL. Noble Financial reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Friday, September 29th. Zacks Investment Research lowered shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. ValuEngine lowered shares of Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a research note on Thursday, September 28th. Finally, Maxim Group set a $15.00 price objective on shares of Anavex Life Sciences Corp. and gave the company a “buy” rating in a research note on Thursday, October 12th.

TRADEMARK VIOLATION NOTICE: “Anavex Life Sciences Corp. (AVXL) Given Consensus Recommendation of “Strong Buy” by Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/11/14/anavex-life-sciences-corp-avxl-given-consensus-recommendation-of-strong-buy-by-brokerages.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in Anavex Life Sciences Corp. during the first quarter worth about $105,000. American International Group Inc. increased its holdings in Anavex Life Sciences Corp. by 7.1% during the first quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock worth $115,000 after buying an additional 1,329 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Anavex Life Sciences Corp. in the second quarter worth about $151,000. Alliancebernstein L.P. purchased a new position in shares of Anavex Life Sciences Corp. in the second quarter worth about $158,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Anavex Life Sciences Corp. by 37.7% in the second quarter. The Manufacturers Life Insurance Company now owns 31,876 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 8,728 shares in the last quarter. Institutional investors and hedge funds own 24.47% of the company’s stock.

Shares of Anavex Life Sciences Corp. (NASDAQ AVXL) opened at $4.03 on Tuesday. Anavex Life Sciences Corp. has a twelve month low of $3.11 and a twelve month high of $6.64.

Anavex Life Sciences Corp. Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get a free copy of the Zacks research report on Anavex Life Sciences Corp. (AVXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.